Molecular assembly of multifunctional 99mTc radiopharmaceuticals using "clickable" amino acid derivatives

ChemMedChem

Volumn 5, Issue 12, 2010, Pages 2026-2038

  Mindt, Thomas L ^a,b   Struthers, Harriet ^b   Spingler, Bernhard ^c   Brans, Luc ^d   Tourwé, Dirk ^d   García Garayoa, Elisa ^e   Schibli, Roger ^b,e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Bombesin; Click chemistry; Imaging agents; Multifunctional conjugates; Technetium

Indexed keywords

ALBUMIN CONJUGATE; ALKYNE DERIVATIVE; AMINO ACID DERIVATIVE; BOMBESIN DERIVATIVE; CHELATING AGENT; COPPER; GASTRIN RECEPTOR; GLUTAMIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TRIFLUOROACETIC ACID;

AMINO ACID SEQUENCE; ARTICLE; BIOCHEMISTRY; CHEMICAL STRUCTURE; CONJUGATION; CYCLOADDITION; DRUG TARGETING; IMAGING; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONE POT SYNTHESIS; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR;

ALKYNES; AMINO ACIDS; AZIDES; BOMBESIN; CATALYSIS; CELL LINE, TUMOR; CLICK CHEMISTRY; COPPER; CRYSTALLOGRAPHY, X-RAY; HUMANS; LYSINE; MOLECULAR CONFORMATION; RADIOPHARMACEUTICALS; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78651473206     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201000342     Document Type: Article

References (48)

1. M. Rudin, R. Weissleder, Nat. Rev. Drug Discovery 2003, 2, 123-131.
2. J. K. Willmann, N. van Bruggen, L. M. Dinkelborg, S. S. Gambhir, Nat. Rev. Drug Discovery 2008, 7, 591-607.
3. R. G. Blasberg, Nucl. Med. Biol. 2003, 30, 879-888.
4. J. M. Park, S. S. Gambhir, Proc. IEEE 2005, 93, 771-783.
5. T. Koullourou, L. S. Natrajan, H. Bhavsar, S. J. A. Pope, J. Feng, J. Narvainen, R. Shaw, E. Scales, R. Kauppinen, A. M. Kenwright, S. Faulkner, J. Am. Chem. Soc. 2008, 130, 2178-2179.
6. V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew. Chem. 2002, 114, 2708-2711.
7. Angew. Chem. Int. Ed. 2002, 41, 2596-2599.
8. C. W. Tornoe, C. Christensen, M. Meldal, J. Org. Chem. 2002, 67, 3057-3064.
9. H. C. Kolb, K. B. Sharpless, Drug Discovery Today 2003, 8, 1128-1137.
10. T. L. Mindt, H. Struthers, L. Brans, T. Anguelov, C. Schweinsberg, V. Maes, D. Tourwé, R. Schibli, J. Am. Chem. Soc. 2006, 128, 15096-15097.
11. R. Alberto, R. Schibli, A. Egli, A. P. Schubiger, U. Abram, T. A. Kaden, J. Am. Chem. Soc. 1998, 120, 7987-7988.
12. T. L. Mindt, C. Müller, M. Melis, M. de Jong, R. Schibli, Bioconjugate Chem. 2008, 19, 1689-1695.
13. T. L. Mindt, C. Schweinsberg, L. Brans, A. Hagenbach, U. Abram, D. Tourwé, E. García-Garayoa, R. Schibli, Chem Med Chem 2009, 4, 529-539.
14. H. Struthers, B. Spingler, T. L. Mindt, R. Schibli, Chem. Eur. J. 2008, 14, 6173-6183.
15. D. R. van Staveren, S. Mundwiler, U. Hoffmanns, J. K. Pak, B. Spingler, N. Metzler-Nolte, R. Alberto, Org. Biomol. Chem. 2004, 2, 2593-2603.
16. K. A. Stephenson, J. Zubieta, S. R. Banerjee, M. K. Levadala, L. Taggart, L. Ryan, N. McFarlane, D. R. Boreham, K. P. Maresca, J. W. Babich, J. F. Valliant, Bioconjugate Chem. 2004, 15, 128-136.
17. See the Supporting Information for details
18. Glycine derivative 2, prepared by the reaction of propargyl amine and bromoacetic acid methyl ester, was previously reported (including an Xray crystal structure of [Re(CO)3(L2)]; see Ref. [13].
19. R. Alberto, A. Egli, U. Abram, K. Hegetschweiler, V. Gramlich, P. A. Schubiger, J. Chem. Soc. Dalton Trans. 1994, 19, 2815-2820.
20. L. J. Farrugia, J. Appl. Crystallogr. 1997, 30, 565.
21. We also investigated the use of SES (trimethylsilylethylsulfonyl) for temporarily masking the N(e) atom of Lys: (S. M. Weinreb, D. M. Demko, T. A. Lessen, J. P. Demers, Tetrahedron Lett. 1986, 27, 2099-2102). However, attempted selective removal of the SES protecting group in the presence of N(a)-Boc was not successful.
22. P. Antunes, M. Ginj, M. A. Walter, J. Chen, J.-C. Reubi, H. R. Mäcke, Bioconjugate Chem. 2007, 18, 84-92.
23. C. Schweinsberg, V. Maes, L. Brans, P. Bläuenstein, D. A. Tourwé, P. A. Schubiger, R. Schibli, E. García-Garayoa, Bioconjugate Chem. 2008, 19, 2432-2439.
24. B. E. Rogers, D. Della Manna, A. Safavy, Cancer Biother. Radiopharm. 2004, 19, 25-34.
25. C. E. Dumelin, S. Trussel, F. Buller, E. Trachsel, F. Bootz, Y. Zhang, L. Mannocci, S. C. Beck, M. Drumea-Mirancea, M. W. Seeliger, C. Baltes, T. Müggler, F. Kranz, M. Rudin, S. Melkko, J. Scheuermann, D. Neri, Angew. Chem. 2008, 120, 3240-3245.
26. Angew. Chem. Int. Ed. 2008, 47, 3196-3201.
27. S. Trussel, C. Dumelin, K. Frey, A. Villa, F. Buller, D. Neri, Bioconjugate Chem. 2009, 20, 2286-2292.
28. O. C. Boerman, F. G. van Schaijk, W. J. G. Oyen, F. H. M. Corstens, J. Nucl. Med. 2003, 44, 400-411.
29. R. F. Vitor, T. Esteves, F. Marques, P. Raposinho, A. Paulo, S. Rodrigues, J. Rueff, S. Casimiro, L. Costa, I. Santos, Cancer Biother. Radiopharm. 2009, 24, 551-563.
30. N. Agorastos, L. Borsig, A. Renard, P. Antoni, G. Viola, B. Spingler, P. Kurz, R. Alberto, Chem. Eur. J. 2007, 13, 3842-3852.
31. T. L. Mindt, C. Müller, F. Stuker, J.-F. Salazar, A. Hohn, T. Müggler, M. Rudin, R. Schibli, Bioconjugate Chem. 2009, 20, 1940-1949.
32. R. F. H. Viguier, A. N. Hulme, J. Am. Chem. Soc. 2006, 128, 11370-11371.
33. J. M. Bryson, T. M. Reineke, PMSE Preprints 2007, 96, 658.
34. Alternatively, CuAAC can be performed with the fully protected intermediate obtained from the coupling reaction of DOTA(tBu)3-NHS ester with precursor 13; however, this requires application of a carefully optimized synthetic procedure, which we recently reported (Ref. [29]). Subsequent removal of the protecting groups (N(a)-Boc of Lys and tertbutyl ester of DOTA) by treatment with TFA followed by complexation with GdCl3 gave L22 in similar yields (see Supporting Information for details).
35. E. García-Garayoa, C. Schweinsberg, V. Maes, L. Brans, P. Bläuenstein, D. A. Tourwé, R. Schibli, P. A. Schubiger, Bioconjugate Chem. 2008, 19, 2409-2416.
36. R. P. J. Schroeder, W. M. van Weerden, C. Bangma, E. P. Krenning, M. de Jong, Methods 2009, 48, 200-204.
37. J. C. Reubi, H. R. Mäcke, J. Nucl. Med. 2008, 49, 1735-1738.
38. C. Hultsch, B. Pawelke, R. Bergmann, F. Wuest, Bioorg. Med. Chem. 2006, 14, 5913-5920.
39. E. García-Garayoa, P. Bläuenstein, A. Blanc, V. Maes, D. Tourwé, P. A. Schubiger, Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 37-47.
40. A. Nguyen, A. E. Reyes, M. Zhang, P. McDonald, W. L. T. Wong, L. A. Damico, M. S. Dennis, Protein Eng. Des. Sel. 2006, 19, 291-297.
41. V. Maes, D. Tourwé, Int. J. Pept. Res. Ther. 2006, 12, 197-202.
42. High uptake of the radiotracer in the kidneys and liver could also be due to renal or hepatobiliary excretion
43. R. Alberto, K. Ortner, N. Wheatley, R. Schibli, A. P. Schubiger, J. Am. Chem. Soc. 2001, 123, 3135-3136.
44. Crys AlisPro Software System, 2007, Oxford Diffraction Ltd., Oxford (UK).
45. A. Altomare, M. C. Burla, M. Camalli, G. L. Cascarano, C. Giacovazzo, A. Guagliardi, A. G. G. Moliterni, G. Polidori, R. Spagna, J. Appl. Crystallogr. 1999, 32, 115-119.
46. M. C. Burla, R. Caliandro, M. Camalli, B. Carrozzini, G. L. Cascarano, L. De Caro, C. Giacovazzo, G. Polidori, R. Spagna, J. Appl. Crystallogr. 2005, 38, 381-388.
47. G. M. Sheldrick, Acta Crystallogr. 2008, A64, 112-122.
48. A. L. Spek, J. Appl. Crystallogr. 2003, 36, 7-13.